Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial

18 Dec 2015

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy
Share to Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 26681678
DOI: 10.1093/annonc/mdv608

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialPMID 26681678Read ↗

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.Semantic proximity Read ↗

Trabectedin as a chemotherapy option for patients with BRCA deficiencySemantic proximity Read ↗

Study finds different treatment responses between BRCA2- and BRCA1-mutated ovarian cancers.Semantic proximity Read ↗

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.Semantic proximity Read ↗

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trialSemantic proximity Read ↗

Ovarian cancer treatment in mutation carriers/BRCAness.Semantic proximity Read ↗

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read ↗

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancerSemantic proximity Read ↗

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.Semantic proximity Read ↗

Now: Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)Semantic proximity Read ↗

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read ↗

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.